A. Johri

671 total citations
19 papers, 301 citations indexed

About

A. Johri is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, A. Johri has authored 19 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in A. Johri's work include Cancer Treatment and Pharmacology (14 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Research Studies (5 papers). A. Johri is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Research Studies (5 papers). A. Johri collaborates with scholars based in Switzerland, United States and France. A. Johri's co-authors include Amit M. Oza, Stan B. Kaye, N. Simon Tchekmedyian, I. Sklenar, Robert S. DiPaola, Celestia S. Higano, Arif Hussain, Ari David Baron, Martin Gore and Jozef Šufliarský and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

A. Johri

19 papers receiving 295 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Johri Switzerland 12 205 109 95 57 36 19 301
Dianne Spillman United States 6 179 0.9× 31 0.3× 144 1.5× 131 2.3× 23 0.6× 8 387
Mohamed Shehata Egypt 12 231 1.1× 40 0.4× 195 2.1× 122 2.1× 9 0.3× 31 458
Krista Menard United States 6 168 0.8× 42 0.4× 188 2.0× 62 1.1× 17 0.5× 9 373
Lina Albitar United States 10 117 0.6× 46 0.4× 204 2.1× 46 0.8× 4 0.1× 12 374
Xin-Jun Dong China 8 164 0.8× 27 0.2× 297 3.1× 96 1.7× 12 0.3× 12 418
Pablo García‐Sanz Spain 11 62 0.3× 27 0.2× 272 2.9× 63 1.1× 19 0.5× 12 387
Cathy Alvarez France 4 151 0.7× 21 0.2× 270 2.8× 55 1.0× 14 0.4× 4 392
Valentina Doneddu Italy 11 117 0.6× 19 0.2× 175 1.8× 66 1.2× 27 0.8× 17 336
Ka Tat Siu United States 10 186 0.9× 62 0.6× 335 3.5× 82 1.4× 105 2.9× 15 500
P. Ravdin United States 6 392 1.9× 22 0.2× 92 1.0× 46 0.8× 9 0.3× 7 515

Countries citing papers authored by A. Johri

Since Specialization
Citations

This map shows the geographic impact of A. Johri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Johri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Johri more than expected).

Fields of papers citing papers by A. Johri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Johri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Johri. The network helps show where A. Johri may publish in the future.

Co-authorship network of co-authors of A. Johri

This figure shows the co-authorship network connecting the top 25 collaborators of A. Johri. A scholar is included among the top collaborators of A. Johri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Johri. A. Johri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Ravandi, Farhad, Iphigenia L. Koumenis, A. Johri, et al.. (2019). Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. Haematologica. 105(6). 1567–1574. 30 indexed citations
2.
Li, Yulan, Qing Liu, Patricia A. Wood, & A. Johri. (2012). Statistical considerations in biosimilar clinical efficacy trials with asymmetrical margins. Statistics in Medicine. 32(3). 393–405. 11 indexed citations
3.
Huinink, W.W. ten Bokkel, Jozef Šufliarský, Willem M. Smit, et al.. (2009). Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study. Journal of Clinical Oncology. 27(19). 3097–3103. 38 indexed citations
4.
Hussain, Arif, Robert S. DiPaola, Ari David Baron, et al.. (2008). Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Annals of Oncology. 20(3). 492–497. 44 indexed citations
5.
Reid, T., Chris H. Takimoto, Claire F. Verschraegen, et al.. (2008). Evaluation of safety, tolerability and pharmacokinetics (PK) of patupilone in patients (pts) with advanced solid tumors and varying degrees of hepatic function: An open-label phase I study. Journal of Clinical Oncology. 26(15_suppl). 2557–2557. 4 indexed citations
6.
Takimoto, Chris H., Siqing Fu, Navneet K. Dhillon, et al.. (2008). Evaluation of pharmacokinetics (PK) and pharmacodynamics (PD) of patupilone and warfarin in patients (pts) with advanced solid tumors: An open-label, phase I study. Journal of Clinical Oncology. 26(15_suppl). 2548–2548. 2 indexed citations
7.
Abrey, Lauren E., Ramaswamy Govindan, James R. Rigas, et al.. (2008). Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label phase II study. Journal of Clinical Oncology. 26(15_suppl). 2033–2033. 15 indexed citations
8.
Abrey, Lauren E., Patrick Y. Wen, Ramaswamy Govindan, et al.. (2007). Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label, multicenter, phase II study. Journal of Clinical Oncology. 25(18_suppl). 18058–18058. 11 indexed citations
9.
Venook, Alan P., Ronnie T.P. Poon, Tony Mok, et al.. (2007). Evaluation of patupilone as monotherapy in patients with advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 25(18_suppl). 15055–15055. 12 indexed citations
10.
11.
Förster, Martin, Stan B. Kaye, Amit M. Oza, et al.. (2007). A Phase Ib and Pharmacokinetic Trial of Patupilone Combined with Carboplatin in Patients with Advanced Cancer. Clinical Cancer Research. 13(14). 4178–4184. 30 indexed citations
12.
13.
Boyer, Michael, Michel Ducreux, M. Liu, et al.. (2006). Efficacy of patupilone in advanced local or metastatic gastric cancer: A phase IIa trial. Journal of Clinical Oncology. 24(18_suppl). 4069–4069. 14 indexed citations
14.
Mellemgaard, Anders, Petr Zatloukal, John Hamm, et al.. (2006). Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC): A phase I/II trial. Journal of Clinical Oncology. 24(18_suppl). 7104–7104. 14 indexed citations
15.
Casado, E., Josep Tabernero, Bohuslav Melichar, et al.. (2006). Patupilone in chemotherapy-pretreated patients with advanced colorectal cancer (CRC) receiving nutritional support and intensive diarrhea management: A phase I multicenter trial. Journal of Clinical Oncology. 24(18_suppl). 3593–3593. 12 indexed citations
16.
Østerlind, Kell, Juan Manuel Sepúlveda-Sánchez, Petr Zatloukal, et al.. (2005). Phase I/II dose escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer. Journal of Clinical Oncology. 23(16_suppl). 7110–7110. 14 indexed citations
17.
Melichar, Bohuslav, Josep Tabernero, E. Casado, et al.. (2005). Phase I dose optimization trial of patupilone in previously treated patients (pts) with advanced colon cancer (ACC). Journal of Clinical Oncology. 23(16_suppl). 3688–3688. 3 indexed citations
18.
Smit, Willem M., Jozef Šufliarský, S. Špánik, et al.. (2005). Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer. Journal of Clinical Oncology. 23(16_suppl). 5056–5056. 21 indexed citations
19.
Gore, Martin, S.B. Kaye, Amit M. Oza, et al.. (2005). Phase I trial of patupilone plus carboplatin in patients with advanced cancer. Journal of Clinical Oncology. 23(16_suppl). 5087–5087. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dianne Spillman Breakdown of academic impact, for papers by Mohamed Shehata Breakdown of academic impact, for papers by Krista Menard Breakdown of academic impact, for papers by Lina Albitar Breakdown of academic impact, for papers by Xin-Jun Dong Breakdown of academic impact, for papers by Pablo García‐Sanz Breakdown of academic impact, for papers by Cathy Alvarez Breakdown of academic impact, for papers by Valentina Doneddu Breakdown of academic impact, for papers by Ka Tat Siu Breakdown of academic impact, for papers by P. Ravdin
Rankless by CCL
2026